Equities

23andMe Holding Co.

ME:NAQ

23andMe Holding Co.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.08 / 2.54%
  • Shares traded1.00
  • 1 Year change-81.29%
  • Beta1.1720
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments216387553
Total Receivables, Net9.081.903.38
Total Inventory121011
Prepaid expenses9.301925
Other current assets, total7.996.789.30
Total current assets255425602
Property, plant & equipment, net7795105
Goodwill, net0352352
Intangibles, net546184
Long term investments------
Note receivable - long term------
Other long term assets1.873.022.59
Total assets3959431,152
LIABILITIES
Accounts payable121338
Accrued expenses507350
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total666465
Total current liabilities127149153
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total797983
Total liabilities207229236
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital2,3622,2212,110
Retained earnings (accumulated deficit)(2173)(1506)(1195)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.62)0.18
Total equity189714916
Total liabilities & shareholders' equity3959431,152
Total common shares outstanding2523232
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.